In vivo delivery of engineered synthetic DNA-encoded SARS-CoV-2 monoclonal antibodies for pre-exposure prophylaxis in non-human primates

COVID-19 remains a major public health concern. Monoclonal antibodies have received emergency use authorization (EUA) for pre-exposure prophylaxis against COVID-19 among high-risk groups for treatment of mild to moderate COVID-19. In addition to recombinant biologics, engineered synthetic DNA-encode...

Full description

Saved in:
Bibliographic Details
Main Authors: Ami Patel, Kyle Rosenke, Elizabeth M. Parzych, Friederike Feldmann, Suman Bharti, Amanda J. Griffin, Blake Schouest, Matt Lewis, Jihae Choi, Neethu Chokkalingam, Viviane Machado, Brian J. Smith, Drew Frase, Ali R. Ali, Jamie Lovaglio, Brian Nguyen, Patrick W. Hanley, Susanne N. Walker, Ebony N. Gary, Abhijeet Kulkarni, Allison Generotti, Joseph R. Francica, Kim Rosenthal, Daniel W. Kulp, Mark T. Esser, Trevor R. F. Smith, Carl Shaia, David B. Weiner, Heinz Feldmann
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Emerging Microbes and Infections
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/22221751.2023.2294860
Tags: Add Tag
No Tags, Be the first to tag this record!